FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM) Low Glucose w/o L-Glutamine: 1X Liquid

FluxMPS™ Dulbecco’s Modified Eagle Medium (DMEM), Low Glucose w/o L-Glutamine: 1X Liquid

FluxMPS™ DCP-DMEML-Q1X is an MPS-grade, 4-stage ultra-filtered DMEM formulated with 1.0 g/L glucose, sodium pyruvate, and sodium bicarbonate — without L-Glutamine — giving researchers full control of nitrogen source supplementation. Processed through a Quadruple-stage filtration system (0.1 µm × 2 + 0.04 µm × 2), it is approximately 5× cleaner than conventional 0.22 µm–filtered media by particulate count and safe for the narrowest microfluidic channels.

• Quadruple-stage nano-filtration: 0.1 µm × 2 passes + 0.04 µm × 2 passes — sub-mycoplasma polishing
• Ultra-low particulate, microchannel-safe — suitable for organ-on-a-chip (OoC) and microphysiological systems (MPS)
• Endotoxin < 0.05 EU/mL (USP <85> BET); sterility confirmed per USP <71> after 14-day incubation
• Formulation: [+] Low Glucose 1.0 g/L, [+] Sodium Pyruvate, [+] Sodium Bicarbonate; [−] L-Glutamine, [−] HEPES
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm) — no ionic interference for biosensors or TEER probes
• ISO Class 5 (Class 100) aseptic fill & finish; ISO 13485:2016 QMS
• Customizable — L-Glutamine, HEPES, pH, glucose level, and other nutrients available on request

Engineered where standard media fails

Conventional 0.22 µm sterilization is inadequate for microfluidic platforms. Subvisible particulates accumulate in narrow channels, mycoplasma-sized contaminants pass through, and elevated endotoxin levels corrupt cytokine signaling and sensor readings. FluxMPS™ DCP-DMEML-Q1X was designed from the ground up for microphysiological systems, organ-on-a-chip devices, and high-precision metabolic studies.^[1,2]

Quadruple-stage filtration system

FluxMPS™ DCP-DMEML-Q1X is the only ready-to-use 0.04 µm DMEM media at this purity level available for organ-on-a-chip and microfluidic research. Each lot passes through four distinct filtration stages — two at 0.1 µm and two at 0.04 µm — inside an ISO Class 5 cleanroom environment, guaranteeing sterility, endotoxin compliance, and mycoplasma exclusion simultaneously.

1. 1

   0.1 µm Pre-filtration I — Large Particulate Removal

   Removes large aggregates, debris, and bulk particulates (≥100 nm). Extends the life of downstream finer filters and reduces bioburden load entering the sterile zone.

2. 2

   0.04 µm Pre-filtration II — Fine Particulate & Mycoplasma Barrier

   Retains fine particulates, bacteria, and mycoplasma species (smallest mycoplasma ≈ 200 nm). Provides the first nano-scale polishing pass and reduces viral load by ≥4 log₁₀ for small non-enveloped viruses.

3. 3

   0.1 µm Sterile-filtration I — Redundancy Pass

   Second-pass sterile filtration providing redundant bioburden reduction. Any contaminant that may have shed from upstream filter housings is captured here before the final polish stage.

4. 4

   0.04 µm Sterile-filtration II — Final Polish & Aseptic Fill

   Ultimate nano-polish under ISO Class 5 (Class 100) conditions. Product flows directly from the 0.04 µm final filter into the final container with zero open-air exposure, ensuring maximum sterility assurance level.

Research applications for FluxMPS™ DMEM Low Glucose w/o L-Glutamine

The L-Glutamine-free, low glucose formulation of DCP-DMEML-Q1X makes it uniquely suited for metabolic flux studies, glutamine restriction experiments, Warburg-effect investigations, and any system where precise nutrient control is paramount. Its MPS-grade purity enables deployment across organ-on-a-chip, microfluidic, and automated bioprocessing platforms.^[3,4]

Automated Bioreactors & Robotics

For the most demanding automated perfusion systems, an optional 0.01 µm (10 nm) ultra-filtered variant of FluxMPS™ DMEM Low Glucose is available by special order. This grade provides total exclusion of nanoparticulates that could foul micro-valve actuators, optical flow sensors, and precision dosing systems in robotic cell culture platforms.

• Total Particulate Exclusion: 10 nm filtration eliminates all particulates that could trigger false-positive sensor events or coat quartz crystal microbalance sensors.
• Valve & Sensor Protection: Prevents protein aggregate deposition on micro-solenoid valve seats and PDMS channel walls during extended perfusion runs.
• Extended Perfusion Stability: Maintains consistent ionic composition and pH over multi-week automated runs without channel occlusion events.

Inquiry Required: The 0.01 µm (10 nm) ultra-filtered grade is produced on a micro-batch schedule. Contact support@diagnocine.com to request this grade and discuss lead times.

Analytical specification sheet — DCP-DMEML-Q1X

All parameters are measured on every production lot and reported in the accompanying Certificate of Analysis (CoA). USP and ISO method references are provided for each critical quality attribute.

Full composition (mg/L)

FluxMPS™ DCP-DMEML-Q1X contains 4× BME amino acid and vitamin concentrations. All ingredient quantities are nominal per-lot targets; actual values are reported in the CoA. Composition is per the original Dulbecco & Freeman (1959) modification used in the source description, exactly as supplied.

Manufacturing standards & compliance

Every batch of FluxMPS™ DCP-DMEML-Q1X is manufactured under a rigorous quality system combining ISO 13485:2016 certification, USP-grade analytical testing, and ISO Class 5 aseptic fill to deliver the reliability that MPS and organ-on-a-chip research demands.

How DCP-DMEML-Q1X compares

FluxMPS™ DCP-DMEML-Q1X was purpose-built for microfluidic and MPS applications where conventional 0.22 µm-filtered DMEM falls short. The table below highlights key differentiation across purity, safety, and engineering compatibility parameters.

Frequently asked questions

Answers to common questions about FluxMPS™ DCP-DMEML-Q1X from organ-on-a-chip researchers, metabolic biologists, and MPS platform engineers.

Supporting literature

The following peer-reviewed references support the science underlying FluxMPS™ MPS-grade media design, organ-on-a-chip methodology, and low-glucose metabolic research applications relevant to DCP-DMEML-Q1X.

1. Bhatia, S.N. & Ingber, D.E. Microfluidic organs-on-chips. Nature Biotechnology 32, 760–772 (2014).doi:10.1038/nbt.2989
2. Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668 (2010).doi:10.1126/science.1188302
3. Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).doi:10.1126/science.123.3191.309
4. DeBerardinis, R.J. et al. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 7, 11–20 (2008).doi:10.1016/j.cmet.2007.10.002
5. Bhimji, S.S. et al. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 22, 1–27 (1996).doi:10.1007/BF00353994
6. van der Meer, A.D. & van den Berg, A. Organs-on-chips: breaking the in vitro impasse. Integrative Biology 4, 461–470 (2012).doi:10.1039/c2ib00176d
7. Ingber, D.E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics 23, 467–491 (2022).doi:10.1038/s41576-022-00466-9
8. Metallo, C.M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2012).doi:10.1038/nature10602
9. Huang, H. et al. Role of glutamine and interlinked asparagine metabolism in vessel formation. EMBO Journal 36, 2334–2352 (2017).doi:10.15252/embj.201695518
10. Jang, K.J. et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integrative Biology 5, 1119–1129 (2013).doi:10.1039/c3ib40049b